Reckitt Bids To Delay Mucinex Competition With Bioequivalance Petition

In an attempt to delay private-label competition for Mucinex OTC cough products, Reckitt Benckiser asks FDA to ensure potential generics meet the same bioequivalence across the 12-hour dosing interval as the branded product